Gene Therapy of Breast Cancer: Studies of Selective Promoter/Enhancer-Modified Vectors to Deliver Suicide Genes

Abstract

The overall goal of this project is to develop gene therapy strategies for breast cancer by translation of studies derived from the DF3/MUCl gene. We have completed Tasks 1 and 2 as outlined in the Statement of Work using the DF3 promoter to selectively drive transgenes in breast cancer cells. The DF3 promoter has been used in an adenoviral vector to selectively detect and eliminate breast cancer cells that contaminate hematopoietic stem cell preparations used in autologous bone marrow transplantation. More recent work has involved modification of the DF3 promoter by adding a Tet-enhancer system to increase expression of the transgenes. The requisite plasmids have been constructed and are being integrated into replication-deficient adenoviral vectors to complete Tasks 3 and 4. Other studies have evaluated transduction of dendritic cells (DC) with adenoviral vectors expressing the DF3/MUCl gene.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 1997
Accession Number
ADA338832

Entities

People

  • Donald W. Kufe

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Animals
  • Blood
  • Bone Marrow
  • Bones
  • Breast Cancer
  • Cells
  • Gene Therapy
  • Immunity
  • Immunization
  • Laboratory Animals
  • Lymphocytes
  • Materials
  • Molecules
  • Neoplasms
  • Stem Cells
  • T Lymphocytes
  • Therapy

Readers

  • Molecular Genetics
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech